Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma

A single institution's experience

Nobuyuki Bandoh, Toshiaki Akahane, Takashi Goto, Michihisa Kono, Haruyuki Ichikawa, Takahiro Sawada, Tomomi Yamaguchi, Hiroshi Nakano, Yumiko Kawase, Yasutaka Kato, Hajime Kamada, Yasuaki Harabuchi, Kazuo Shimizu, Hiroshi Nishihara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Thyroid carcinoma (TC) has characteristic genetic alterations, including point mutations in proto-oncogenes and chromosomal rearrangements that vary by histologic subtype. Recent developments in next-generation sequencing (NGS) technology enable simultaneous analysis of cancer-associated genes of interest, thus improving diagnostic accuracy and allowing precise personalized treatment for human cancer. A total of 50 patients who underwent thyroidectomy between 2014 and 2016 at Hokuto Hospital were enrolled. Total DNA was extracted from formalin-fixed, paraffin-embedded tissue sections and quantified. Targeted regions of 24 cancer-associated genes were amplified by PCR, barcoded and sequenced using an Illumina MiSeq platform. Subjects included 30 patients with papillary carcinoma (PC), two with PC tall cell variant (TVPC), two with PC follicular variant (FVPC), eight with follicular carcinoma, seven with poorly differentiated carcinoma (PDC), and one with anaplastic carcinoma (AC). The BRAF V600E mutation was present in 25 of 30 (83%) patients with PC, 2 of 2 (100%) patients with TVPC, 6 of 7 (86%) patients of PDC, and one patient with AC. PIK3CA mutations were present in 3 of 30 (delPV104P, A1046T and C420R; 10%) patients with PC and 1 of 7 (H1047R; 14%) patients with PDC. The TP53 mutation was present in 1 of 30 (R306*; 3.3%) patients with PC and 1 of 7 (Q152*; 14%) patients with PDC. The NRAS mutation was present in 1 of 2 (Q61K, 50%) patients with FVPC. Statistical analysis showed that patients without the BRAF V600E mutation had advanced pathologic T and N stages compared with those with the mutation (P=0.047 and P=0.019, respectively). The BRAF V600E mutation was not correlated with overall and disease-free survival in patients with PC. A patient with PC with a mutation in EGFR (K852Q) and the PIK3CA mutation had an aggressive course with multiple bone and lung metastases. Detection of mutations in cancer-associated genes using NGS could enhance the understanding of the clinical behavior of TC.

Original languageEnglish
Pages (from-to)7278-7286
Number of pages9
JournalOncology Letters
Volume16
Issue number6
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Neoplasm Genes
Thyroid Neoplasms
Papillary Carcinoma
Mutation
Carcinoma
Carcinoma, Papillary, Follicular
Proto-Oncogenes
Thyroidectomy
Point Mutation
Paraffin
Formaldehyde
Disease-Free Survival

Keywords

  • BRAF
  • Next-generation sequencing
  • Papillary carcinoma
  • PIK3CA
  • Thyroid carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma : A single institution's experience. / Bandoh, Nobuyuki; Akahane, Toshiaki; Goto, Takashi; Kono, Michihisa; Ichikawa, Haruyuki; Sawada, Takahiro; Yamaguchi, Tomomi; Nakano, Hiroshi; Kawase, Yumiko; Kato, Yasutaka; Kamada, Hajime; Harabuchi, Yasuaki; Shimizu, Kazuo; Nishihara, Hiroshi.

In: Oncology Letters, Vol. 16, No. 6, 01.12.2018, p. 7278-7286.

Research output: Contribution to journalArticle

Bandoh, N, Akahane, T, Goto, T, Kono, M, Ichikawa, H, Sawada, T, Yamaguchi, T, Nakano, H, Kawase, Y, Kato, Y, Kamada, H, Harabuchi, Y, Shimizu, K & Nishihara, H 2018, 'Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma: A single institution's experience', Oncology Letters, vol. 16, no. 6, pp. 7278-7286. https://doi.org/10.3892/ol.2018.9538
Bandoh, Nobuyuki ; Akahane, Toshiaki ; Goto, Takashi ; Kono, Michihisa ; Ichikawa, Haruyuki ; Sawada, Takahiro ; Yamaguchi, Tomomi ; Nakano, Hiroshi ; Kawase, Yumiko ; Kato, Yasutaka ; Kamada, Hajime ; Harabuchi, Yasuaki ; Shimizu, Kazuo ; Nishihara, Hiroshi. / Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma : A single institution's experience. In: Oncology Letters. 2018 ; Vol. 16, No. 6. pp. 7278-7286.
@article{47a47f51292a4405a10eba0f2d1cfd8c,
title = "Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma: A single institution's experience",
abstract = "Thyroid carcinoma (TC) has characteristic genetic alterations, including point mutations in proto-oncogenes and chromosomal rearrangements that vary by histologic subtype. Recent developments in next-generation sequencing (NGS) technology enable simultaneous analysis of cancer-associated genes of interest, thus improving diagnostic accuracy and allowing precise personalized treatment for human cancer. A total of 50 patients who underwent thyroidectomy between 2014 and 2016 at Hokuto Hospital were enrolled. Total DNA was extracted from formalin-fixed, paraffin-embedded tissue sections and quantified. Targeted regions of 24 cancer-associated genes were amplified by PCR, barcoded and sequenced using an Illumina MiSeq platform. Subjects included 30 patients with papillary carcinoma (PC), two with PC tall cell variant (TVPC), two with PC follicular variant (FVPC), eight with follicular carcinoma, seven with poorly differentiated carcinoma (PDC), and one with anaplastic carcinoma (AC). The BRAF V600E mutation was present in 25 of 30 (83{\%}) patients with PC, 2 of 2 (100{\%}) patients with TVPC, 6 of 7 (86{\%}) patients of PDC, and one patient with AC. PIK3CA mutations were present in 3 of 30 (delPV104P, A1046T and C420R; 10{\%}) patients with PC and 1 of 7 (H1047R; 14{\%}) patients with PDC. The TP53 mutation was present in 1 of 30 (R306*; 3.3{\%}) patients with PC and 1 of 7 (Q152*; 14{\%}) patients with PDC. The NRAS mutation was present in 1 of 2 (Q61K, 50{\%}) patients with FVPC. Statistical analysis showed that patients without the BRAF V600E mutation had advanced pathologic T and N stages compared with those with the mutation (P=0.047 and P=0.019, respectively). The BRAF V600E mutation was not correlated with overall and disease-free survival in patients with PC. A patient with PC with a mutation in EGFR (K852Q) and the PIK3CA mutation had an aggressive course with multiple bone and lung metastases. Detection of mutations in cancer-associated genes using NGS could enhance the understanding of the clinical behavior of TC.",
keywords = "BRAF, Next-generation sequencing, Papillary carcinoma, PIK3CA, Thyroid carcinoma",
author = "Nobuyuki Bandoh and Toshiaki Akahane and Takashi Goto and Michihisa Kono and Haruyuki Ichikawa and Takahiro Sawada and Tomomi Yamaguchi and Hiroshi Nakano and Yumiko Kawase and Yasutaka Kato and Hajime Kamada and Yasuaki Harabuchi and Kazuo Shimizu and Hiroshi Nishihara",
year = "2018",
month = "12",
day = "1",
doi = "10.3892/ol.2018.9538",
language = "English",
volume = "16",
pages = "7278--7286",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma

T2 - A single institution's experience

AU - Bandoh, Nobuyuki

AU - Akahane, Toshiaki

AU - Goto, Takashi

AU - Kono, Michihisa

AU - Ichikawa, Haruyuki

AU - Sawada, Takahiro

AU - Yamaguchi, Tomomi

AU - Nakano, Hiroshi

AU - Kawase, Yumiko

AU - Kato, Yasutaka

AU - Kamada, Hajime

AU - Harabuchi, Yasuaki

AU - Shimizu, Kazuo

AU - Nishihara, Hiroshi

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Thyroid carcinoma (TC) has characteristic genetic alterations, including point mutations in proto-oncogenes and chromosomal rearrangements that vary by histologic subtype. Recent developments in next-generation sequencing (NGS) technology enable simultaneous analysis of cancer-associated genes of interest, thus improving diagnostic accuracy and allowing precise personalized treatment for human cancer. A total of 50 patients who underwent thyroidectomy between 2014 and 2016 at Hokuto Hospital were enrolled. Total DNA was extracted from formalin-fixed, paraffin-embedded tissue sections and quantified. Targeted regions of 24 cancer-associated genes were amplified by PCR, barcoded and sequenced using an Illumina MiSeq platform. Subjects included 30 patients with papillary carcinoma (PC), two with PC tall cell variant (TVPC), two with PC follicular variant (FVPC), eight with follicular carcinoma, seven with poorly differentiated carcinoma (PDC), and one with anaplastic carcinoma (AC). The BRAF V600E mutation was present in 25 of 30 (83%) patients with PC, 2 of 2 (100%) patients with TVPC, 6 of 7 (86%) patients of PDC, and one patient with AC. PIK3CA mutations were present in 3 of 30 (delPV104P, A1046T and C420R; 10%) patients with PC and 1 of 7 (H1047R; 14%) patients with PDC. The TP53 mutation was present in 1 of 30 (R306*; 3.3%) patients with PC and 1 of 7 (Q152*; 14%) patients with PDC. The NRAS mutation was present in 1 of 2 (Q61K, 50%) patients with FVPC. Statistical analysis showed that patients without the BRAF V600E mutation had advanced pathologic T and N stages compared with those with the mutation (P=0.047 and P=0.019, respectively). The BRAF V600E mutation was not correlated with overall and disease-free survival in patients with PC. A patient with PC with a mutation in EGFR (K852Q) and the PIK3CA mutation had an aggressive course with multiple bone and lung metastases. Detection of mutations in cancer-associated genes using NGS could enhance the understanding of the clinical behavior of TC.

AB - Thyroid carcinoma (TC) has characteristic genetic alterations, including point mutations in proto-oncogenes and chromosomal rearrangements that vary by histologic subtype. Recent developments in next-generation sequencing (NGS) technology enable simultaneous analysis of cancer-associated genes of interest, thus improving diagnostic accuracy and allowing precise personalized treatment for human cancer. A total of 50 patients who underwent thyroidectomy between 2014 and 2016 at Hokuto Hospital were enrolled. Total DNA was extracted from formalin-fixed, paraffin-embedded tissue sections and quantified. Targeted regions of 24 cancer-associated genes were amplified by PCR, barcoded and sequenced using an Illumina MiSeq platform. Subjects included 30 patients with papillary carcinoma (PC), two with PC tall cell variant (TVPC), two with PC follicular variant (FVPC), eight with follicular carcinoma, seven with poorly differentiated carcinoma (PDC), and one with anaplastic carcinoma (AC). The BRAF V600E mutation was present in 25 of 30 (83%) patients with PC, 2 of 2 (100%) patients with TVPC, 6 of 7 (86%) patients of PDC, and one patient with AC. PIK3CA mutations were present in 3 of 30 (delPV104P, A1046T and C420R; 10%) patients with PC and 1 of 7 (H1047R; 14%) patients with PDC. The TP53 mutation was present in 1 of 30 (R306*; 3.3%) patients with PC and 1 of 7 (Q152*; 14%) patients with PDC. The NRAS mutation was present in 1 of 2 (Q61K, 50%) patients with FVPC. Statistical analysis showed that patients without the BRAF V600E mutation had advanced pathologic T and N stages compared with those with the mutation (P=0.047 and P=0.019, respectively). The BRAF V600E mutation was not correlated with overall and disease-free survival in patients with PC. A patient with PC with a mutation in EGFR (K852Q) and the PIK3CA mutation had an aggressive course with multiple bone and lung metastases. Detection of mutations in cancer-associated genes using NGS could enhance the understanding of the clinical behavior of TC.

KW - BRAF

KW - Next-generation sequencing

KW - Papillary carcinoma

KW - PIK3CA

KW - Thyroid carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85055181765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055181765&partnerID=8YFLogxK

U2 - 10.3892/ol.2018.9538

DO - 10.3892/ol.2018.9538

M3 - Article

VL - 16

SP - 7278

EP - 7286

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 6

ER -